Delving into the Latest Updates on Changzhou Humon Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Urogenital Diseases

Digestive System Disorders

Small molecule drug

Antibody drug conjugate (ADC)

Bispecific antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	7
Immune System Diseases	2
Endocrinology and Metabolic Disease	1
Hemic and Lymphatic Diseases	1
Infectious Diseases	1

Top 5 Drug Type	Count

Small molecule drug	3
Antibody drug conjugate (ADC)	3
Bispecific antibody	2
Biological products	2
Monoclonal antibody	1

Top 5 Target	Count

CDH17(Cadherin-17)	1
ROR1(Inactive tyrosine-protein kinase transmembrane receptor ROR1)	1
TYK2(Tyrosine-protein kinase 2)	1
EGFR x c-Met	1
CLL-1(C-Type lectin domain family 12 member A)	1

主要研究目的：评价各联合治疗方案在晚期实体瘤患者中的安全性和耐受性。次要研究目的： 1. 评价各联合治疗方案在晚期实体瘤患者中的有效性； 2. 评价联合治疗方案中HS-20093静脉注射给药在晚期实体瘤患者中的PK特征； 3. 评价联合治疗方案中HS-20093的免疫原性。

[Translation]

Main study objectives: To evaluate the safety and tolerability of each combination therapy in patients with advanced solid tumors. Secondary study objectives: 1. To evaluate the effectiveness of each combination therapy in patients with advanced solid tumors; 2. To evaluate the PK characteristics of HS-20093 intravenously administered in combination therapy in patients with advanced solid tumors; 3. To evaluate the immunogenicity of HS-20093 in combination therapy.

Start Date26 Apr 2024

Sponsor / Collaborator

Shanghai Hansoh Biomedical Co. Ltd.

[+1]

CTR20241023 / RecruitingPhase 1

注射用HS-20089 联合治疗在晚期实体瘤受试者中的安全性、耐受性、药代动力学和有效性的I期临床研究（队列1：本品联合阿得贝利单抗、队列3：本品联合贝伐珠单抗）

[Translation] Phase I clinical study on the safety, tolerability, pharmacokinetics and efficacy of HS-20089 for injection in combination therapy in subjects with advanced solid tumors (cohort 1: HS-20089 combined with adebelimumab, cohort 3: HS-20089 combined with bevacizumab)

评价HS-20089 联合治疗在晚期实体瘤受试者中的安全性和耐受性。

[Translation]

To evaluate the safety and tolerability of HS-20089 combination therapy in subjects with advanced solid tumors.

Start Date11 Apr 2024

Sponsor / Collaborator

Shanghai Hansoh Biomedical Co. Ltd.

[+1]

100 Clinical Results associated with Changzhou Humon Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Changzhou Humon Pharmaceutical Co., Ltd.

Login to view more data

2

Literatures (Medical) associated with Changzhou Humon Pharmaceutical Co., Ltd.

Guangdong Huagong

An highly Effective Synthesis Process of Chk1 Inhibitor GDC-0575

Author: Wang Mingyuan ; Hu Jinyang ; Zhang Tao

GDC-0575, as a novel oral small-mol. Chk1 inhibitor, has attracted the attention of many pharmaceutical companies due to its strong synergistic effect with gemcitabine in sarcoma cells.Therefore, it is particularly important to develop an efficient synthesis process for preparing GDC-0575. 1 H-pyrrolo [2, 3-b] pyridine with a wide range of sources and low price was used as starting material.High quality GDC-0575 was obtained with a total yield of 25.2 %, which underwent eight steps of oxidation, chlorination, nitration, bromination, aromatic nucleophilic substitution, hydrogenation, condensation and deprotection, resp.The purity of API reached 98.8 %, which met the requirements of pharmacol. and toxicol. studies in the early stage.

Guangdong Huagong

Study on the Synthesis Process of the Key Intermediate(2R, 5S)-5-((benzyloxy)amino)Piperidine-2-carboxylic Acid of Relebactam

Author: Wang Pengfei ; Hu Jinyang ; Dong Jizhe

Relebactam is a new diazabicyclooctanone compound developed by Merck, a pharmaceutical giant in the United States.Relebactam is a broad-spectrum β-lactamase inhibitor.In fact, the efficient and inexpensive synthesis of the key chiral piperidine intermediate 1 is of vital importance for the com. production of relebactam.The main work of this paper is to find the highly efficient selective reduction of oxime ether by CeCl_3/NaBH_4 system.Then the process parameters are studied and the process is verified.The yield of best synthesis process is increased to 86 %.This synthesis process has the advantages of high reduction selectivity, low cost and high yield.

100 Deals associated with Changzhou Humon Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Changzhou Humon Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

Preclinical

IND Application

1

IND Approval

Phase 1 Clinical

4

2

Phase 2 Clinical

Phase 3 Clinical

1

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

HS-10374 ( TYK2 )	Plaque psoriasis More	Phase 3
HS-10390 ( AT1R x ETA )	Glomerulonephritis, IGA More	Phase 2
HS-10384	Vasomotor symptom More	Phase 2
PM-1080 ( EGFR x c-Met )	EGFR positive Non-squamous non-small cell lung cancer More	Phase 1
HS-20105 ( Trop-2 )	Advanced Malignant Solid Neoplasm More	Phase 1